newsfilter
← Latest News
GlobeNewswire·

NeOnc Insider Buying Expands Ahead of FDA Discussions and Two Key Brain Cancer Data Presentations

NTHI
  • NeOnc Technologies Holdings (NASDAQ: NTHI) CEO Amir F. Heshmatpour purchased 80,000 shares between November 9-11 for approximately $333,100, raising his total direct holdings to 3,333,000 shares.
  • Chief Medical Officer Thomas C. Chen bought 5,016 shares via his IRA on November 9-10 for approximately $20,000.
  • The FDA granted a Type B End-of-Phase meeting scheduled for early January 2027 to discuss an accelerated approval pathway for intranasal NEO100 under Section 506(c).
  • NeOnc plans to seek FDA agreement on the design of the NEO100-012 Phase 3 trial, which will compare the therapy against standard-of-care chemotherapy in patients with recurrent IDH-mutant grade 4 astrocytoma.
  • The proposed Phase 3 strategy involves ongoing enrollment at the time of any accelerated-approval application, with a final overall survival analysis intended to support conversion to traditional approval.
  • NeOnc will present updated NEO100 Phase 1/2a & compassionate-use data (abstract CTNI-26) & NEO212 Phase 1 safety & early activity data (abstract CTNI-27) at the Society for Neuro-Oncology meeting on November 13, 2026.
  • August 2026 Phase 2a results for NEO100 showed a 48.9% six-month progression-free survival rate compared to a 20% historical benchmark, with a median overall survival of 26.09 months & no major toxicities.
  • Four analyst firms (BTIG, Roth MKM, Maxim Group, Alliance Global Partners) maintain Buy ratings on NeOnc with price targets ranging from $13 to $20.
  • Short interest in NTHI exceeded 920,000 shares as of October 30, representing over 7 days to cover based on average trading volume.
  • NeOnc signed a memorandum of understanding with the Department of Health – Abu Dhabi in October 2026 to explore clinical trial opportunities, specialist training, & potential regional manufacturing.
  • Upcoming key milestones include the SNO presentation on November 13, the FDA meeting in early January 2027, & the subsequent review of official meeting minutes.
Company
24/7 Market News and NeOnc Technology
Keywords
Nasdaq:NTHI, 24/7 Market News and NeOnc Technology, $NTHI, FDA, Phase 3, cancer, oncology, Insider Buying, Buy, UAE